Alterity Therapeutics Ltd. · ASX:ATH
Alterity Therapeutics — Shareholder Meeting (November 2024)
17 slides from Alterity Therapeutics's shareholder meeting presentation, Nov 22, 2024
Slide 1: AGM - David Stamler, MD, CEO
For personal use only David Stamler, MD AGM CEO 22 November 2024
Slide 2: Forward Looking Statements
For personal use only Forward Looking Statements This presentation may contain some statements that may be considered “Forward-Looking Statements”, within the meaning of the US Securities Laws. Thus, any forward-looking statement relating to financial projections or other statements relating to the
Slide 3: Targeting Iron-Related Neurodegenerative Diseases
Targeting Iron-Related Neurodegenerative Diseases • Iron: central to pathology of many neurodegenerative For personal use only diseases Friedreich Ataxia • Parkinsonian disorders include • Parkinson’s disease (PD) • Rare diseases with similar motor symptoms • Multiple System Atrophy (MSA) Multiple •
Slide 4: Promising Portfolio in Neurodegenerative Diseases
Promising Portfolio in Neurodegenerative Diseases For personal use only ASSET PHASE PARTNER PRE- NATURAL PARTNER / PROGRAM INDICATION DISCOVERY PHASE 1 PHASE 2 CLINICAL HISTORY COLLABORATOR Multiple System Atrophy ATH434-201 Enrollment Complete Early Stage Multiple System Atrophy Enrollment Complete
Slide 5: Significant Commercial Opportunity in Treating Multiple System Atrophy
Significant Commercial Opportunity in Treating Multiple System Atrophy For personal use only Substantial Unmet Need Strong Intent to Prescribe Severely debilitating illnesses Motivated by efficacy of treating with no current treatments are the underlying disease and not ripe for new entrants targeti
Slide 6: Alpha-Synuclein and Iron in Health
Alpha-Synuclein and Iron in Health α-Synuclein protein For personal use only • Critical for normal function of neurons • Enables nerves to communicate with α-Synuclein each other via neurotransmitters Iron is Essential for Life • Red blood cell production, oxygen transport • Neurotransmitter synthes
Slide 7: Increased Brain Iron in Parkinson's Disease and Multiple System Atrophy
Increased Brain Iron in Parkinson’s Disease and Multiple System Atrophy Parkinson’s disease Multiple System Atrophy For personal use only n=7 * Patients Substantia nigra (T) n=8 n=9 Cerebral cortex Healthy n = 11 n=8 * Substantia nigra (pc) n=3 n=8 * Caudate nucleus n = 13 n = 10 Cerebellum n = 24 n
Slide 8: Treatment Approach: Address Underlying Pathology
Treatment Approach: Address Underlying Pathology For personal use only Reduce α‐synuclein Redistribute excess aggregation labile iron Rescue brain cells/ and neuronal function in the CNS Oxidative injury Potential Disease Modifying Therapy for MSA 8
Slide 9: ATH434: Potential Disease Modifying Therapy
ATH434: Potential Disease Modifying Therapy ATH434 binding to iron For personal use only • Small molecule drug candidate • Decreases pathologic protein aggregation (α-synuclein) in CNS • Iron chaperone: redistributes excess labile iron in CNS • Oral medication • Preferred over infusions and injectio
Slide 10: Multiple System Atrophy (MSA): Rare, Highly Debilitating and Rapidly Progressive Neurodegenerative Disease
Multiple System Atrophy (MSA): Rare, Highly Debilitating and Rapidly Progressive Neurodegenerative Disease For personal use only • Parkinsonian disorder with no approved treatment • Orphan disease: up to 50,000 patients in U.S. • Disease characteristics • Motor: Parkinsonism, uncoordinated movements
Slide 11: Ongoing Treatment Studies with ATH434
Ongoing Treatment Studies with ATH434 Study ATH434-201 – Phase 2 ATH434-202 – Phase 2 For personal use only Design Randomized, double-blind Single arm, open-label Objectives Efficacy and safety of ATH434 Efficacy and safety of ATH434 Population Early-stage MSA Advanced MSA Sample Size N = 77 N = 10
Slide 12: ATH434-202 Interim Clinical Data Confirms Development Approach
ATH434-202 Interim Clinical Data Confirms Development Approach Population: 10 with advanced MSA For personal use only Treatment: ATH434 75 mg bid Assessment: 6 months Safety: ATH434 well-tolerated and had no serious adverse events related to study drug Areas Assessed • Speech • Walking UMSARS: Unifi
Slide 13: ATH434-202 Interim Biomarker Data Support Clinical Observations
ATH434-202 Interim Biomarker Data Support Clinical Observations For personal use only Brain Iron Brain Volume Neuronal Injury Marker % change in CSF NfL at 6mon 80 60 40 20 0 -20 -40 ATH434-202 bioMuse Iron content was stable in Brain volume stable Mean levels of NfL, a marker of the s. nigra, putam
Slide 14: Target Measures for Success
Target Measures for Success For personal use only Favorable Safety Profile / No Drug Related Serious Adverse Events MSA Evidence of Drug Effect on Biomarker Endpoint or Phase 2 Evidence of Benefit on Clinical Endpoint Relevant to MSA ATH434-201 Safety and Efficacy Data Support Advancing to Phase 3 1
Slide 15: Key Milestones
Key Milestones ATH434-201 For personal use only ATH434-202 Preliminary Phase 2 Trial 6 mo Data Topline Data BioMUSE ATH434-201 Data Phase 2 Trial Study Complete ATH434 MoA data Scientific Meeting Presentations Jan 24 Feb 24 Mar 24 Apr 24 May 24 Jun 24 Jul 24 Aug 24 Sep 24 Oct 24 Nov 24 Dec 24 Jan 25
Slide 16: Alterity: Poised for Progress
Alterity: Poised for Progress • Targeting Orphan disease with no approved For personal use only Catalysts treatments MSA Natural History Study • Natural History Study de-risked Phase 2 H1 2024: Present new biomarker • Positive interim data in open label study data confirms clinical development app
Slide 17: For personal use only
For personal use only ASX:ATH | NASDAQ:ATHE
Alterity Therapeutics — Shareholder Meeting (November 2024) on 6ix